Qsensus

Qsensus is a biotechnology company specializing in ultra-sensitive genetic detection technologies for liquid biopsy and clinical diagnostics. The company's core platform, Q-SENS (Quantitative Sequencing of Extremely rare Nucleotide Substitutions), enables the detection of rare genetic mutations with high precision by significantly reducing sequencing errors. This technology is primarily applied in oncology for early cancer detection, monitoring minimal residual disease (MRD), and therapy selection. Founded by researchers from the University of California, San Diego, Qsensus leverages advanced molecular barcoding and bioinformatics to achieve detection limits below 0.01% allele frequency. The company provides tools and services that allow clinicians and researchers to identify actionable mutations from non-invasive blood samples. Qsensus aims to advance the field of precision medicine by providing the accuracy required for reliable clinical decision-making in cancer care.